



# SAFETY DATA SHEET

Revision date 13-Jun-2025

Version 3

Page 1 / 12

## Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

### 1.1. Product identifier

**Product Name** Aminocaproic Acid Injection (Hospira Inc.)  
**Product Code(s)** PZ03068  
**Trade Name:** Not applicable  
**Chemical Family:** Not determined

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

**Recommended Use** Pharmaceutical product

### 1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company  
275 North Field Drive  
Lake Forest, Illinois 60045  
1-800-879-3477

Pfizer Ireland Pharmaceuticals  
OSG Building  
Ringaskiddy, Co. Cork.  
Ireland  
+353 21 4378701

**E-mail address** pfizer-MSDS@pfizer.com

### 1.4. Emergency telephone number

**Emergency Telephone** Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

## Section 2: HAZARDS IDENTIFICATION

### 2.1. Classification of the substance or mixture

Not classified as hazardous.

#### OSHA Classification

**Hazards not otherwise classified (HNOC)**

Not applicable

**Hazards classified under paragraph (d)(1)(ii) of 1910.1200**

Not applicable

### 2.2. Label elements

**Signal word** Not classified

**Hazard statements** Not classified in accordance with international standards for workplace safety.

### 2.3. Other hazards

**Other hazards** An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

# SAFETY DATA SHEET

Product Name Aminocaproic Acid Injection (Hospira Inc.)  
Revision date 13-Jun-2025

Page 2 / 12  
Version 3

## PBT & vPvB

The product does not contain any substance(s) classified as PBT or vPvB.

## Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors.

## Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

### 3.1 Substances

#### Substances

Not applicable

### 3.2 Mixtures

#### Hazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
+ Hydrochloric Acid (CAS #: 7647-01-0)	***	-	231-595-7 (017-002-00-2) (017-002-01-X)	Press. Gas Skin Corr. 1A (H314) Acute Tox. 3 (H331)	Eye Irrit. 2 :: 10%≤C<25% Skin Corr. 1B :: C≥25% Skin Irrit. 2 :: 10%≤C<25% STOT SE 3 :: C≥10%	No data available	No data available

#### NonHazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified	Not classified	No data available	No data available
Aminocaproic Acid (CAS #: 60-32-2)	25		200-469-3	Not classified	Not classified	No data available	No data available

## Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate No information available

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Aminocaproic Acid 60-32-2	>10000	No data available	No data available	No data available	No data available

# SAFETY DATA SHEET

Product Name Aminocaproic Acid Injection (Hospira Inc.)  
Revision date 13-Jun-2025

Page 3 / 12  
Version 3

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
+ Hydrochloric Acid 7647-01-0	238	5010	No data available	No data available	563.3022

This product does not contain candidate substances of very high concern at a concentration  $\geq 0.1\%$  (Regulation (EC) No. 1907/2006 (REACH), Article 59).

## Additional information

\* Proprietary

\*\* to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Non-hazardous ingredients provided for completeness.

## Section 4: FIRST AID MEASURES

### 4.1. Description of first aid measures

Inhalation	Move victim to fresh air.
Eye contact	If symptoms persist, call a physician.
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

### 4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
-------------------------------------	--

### 4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians	None.
--------------------	-------

## Section 5: FIRE-FIGHTING MEASURES

### 5.1. Extinguishing media

Suitable Extinguishing Media	Dry chemical, CO2, alcohol-resistant foam or water spray.
------------------------------	---

### 5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical	Fine particles (such as dust and mists) may fuel fires/explosions.
Hazardous combustion products	Formation of toxic gases is possible during heating or fire.
Explosion data	
Sensitivity to mechanical impact	No information available.
Sensitivity to static discharge	No information available.

### 5.3. Advice for firefighters

# SAFETY DATA SHEET

Product Name Aminocaproic Acid Injection (Hospira Inc.)  
Revision date 13-Jun-2025

Page 4 / 12  
Version 3

**Special protective equipment and precautions for fire-fighters** Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

## Section 6: ACCIDENTAL RELEASE MEASURES

### 6.1. Personal precautions, protective equipment and emergency procedures

**Personal precautions** Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.  
**For emergency responders** Use personal protection recommended in Section 8.

### 6.2. Environmental precautions

**Environmental precautions** Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### 6.3. Methods and material for containment and cleaning up

**Methods for containment** Prevent further leakage or spillage if safe to do so.  
**Methods for cleaning up** Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.  
**Prevention of secondary hazards** Clean contaminated objects and areas thoroughly observing environmental regulations.

### 6.4. Reference to other sections

**Reference to other sections** See section 8 for more information. See section 13 for more information.

## Section 7: HANDLING AND STORAGE

### 7.1. Precautions for safe handling

**Advice on safe handling** Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.  
**General hygiene considerations** Handle in accordance with good industrial hygiene and safety practice.

### 7.2. Conditions for safe storage, including any incompatibilities

**Storage Conditions** Handle and store per label and other instructions to maintain product integrity.

### 7.3. Specific end use(s)

**Specific use(s)** Pharmaceutical product.

## Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

### 8.1. Control parameters

#### Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

#### Aminocaproic Acid

# SAFETY DATA SHEET

Product Name Aminocaproic Acid Injection (Hospira Inc.)  
Revision date 13-Jun-2025

Page 5 / 12  
Version 3

Pfizer OEL TWA-8 Hr:	3000 µg/m <sup>3</sup>
<b>Aminocaproic Acid</b>	
Russia	MAC: 2 mg/m <sup>3</sup>
<b>+ Hydrochloric Acid</b>	
ACGIH OEL (Ceiling)	2 ppm
ACGIH TLV	Ceiling: 2 ppm
Austria	TWA-TMW: 5 ppm; TWA-TMW: 8 mg/m <sup>3</sup> ; STEL-KZGW: 10 ppm (8 X 5 min); STEL-KZGW: 15 mg/m <sup>3</sup> (8 X 5 min);
Bulgaria	TWA: 5 ppm; TWA: 8.0 mg/m <sup>3</sup> ; STEL: 10 ppm; STEL: 15.0 mg/m <sup>3</sup> ;
Czech Republic	8 mg/m <sup>3</sup> Ceiling: 15 mg/m <sup>3</sup>
Denmark	STEL: 5 ppm; STEL: 8 mg/m <sup>3</sup> ;
Estonia	TWA: 5 ppm; TWA: 8 mg/m <sup>3</sup> ; STEL: 10 ppm; STEL: 15 mg/m <sup>3</sup> ;
European Union	TWA: 5 ppm; TWA: 8 mg/m <sup>3</sup> ; STEL: 10 ppm; STEL: 15 mg/m <sup>3</sup> ;
Finland	STEL: 5 ppm; STEL: 7.6 mg/m <sup>3</sup> ;
Germany DFG	TWA-MAK: 2 ppm; I(2); TWA-MAK: 3.0 mg/m <sup>3</sup> ; I(2); Peak: 4 ppm; Peak: 6 mg/m <sup>3</sup> ;
Germany TRGS	TWA-AGW; 2 ppm (exposure factor 2); TWA-AGW; 3 mg/m <sup>3</sup> (exposure factor 2);
Hungary	TWA-AK: 8 mg/m <sup>3</sup> ; TWA-AK: 5 ppm; STEL-CK: 165 mg/m <sup>3</sup> ; STEL-CK: 10 ppm;
Ireland	TWA: 8 mg/m <sup>3</sup> ; TWA: 5 ppm; STEL: 10 ppm; STEL: 15 mg/m <sup>3</sup> ;
Italy MDLPS	TWA: 5 ppm; TWA: 8 mg/m <sup>3</sup> ; STEL: 10 ppm; STEL: 15 mg/m <sup>3</sup> ;
Ceiling Limit Value	2 ppm 3.0 mg/m <sup>3</sup>
Latvia	TWA: 5 ppm; TWA: 8 mg/m <sup>3</sup> ; STEL: 10 ppm; STEL: 15 mg/m <sup>3</sup> ;
Netherlands	TWA: 5 ppm; TWA: 8 mg/m <sup>3</sup> ; STEL: 10 ppm; STEL: 15 mg/m <sup>3</sup> ;
Poland	TWA-NDS: 5 mg/m <sup>3</sup> ; STEL-NDSch: 10 mg/m <sup>3</sup> ;

# SAFETY DATA SHEET

Product Name Aminocaproic Acid Injection (Hospira Inc.)  
Revision date 13-Jun-2025

Page 6 / 12  
Version 3

Romania	TWA: 5 ppm; TWA: 8 mg/m <sup>3</sup> ; STEL: 10 ppm; STEL: 15 mg/m <sup>3</sup> ;
Russia	MAC: 5 mg/m <sup>3</sup>
Slovakia	TWA: 5 ppm; TWA: 8.0 mg/m <sup>3</sup> ; Ceiling: 15 mg/m <sup>3</sup> ;
Spain	TWA-(VLA-ED): 5 ppm; TWA-(VLA-ED): 7.6 mg/m <sup>3</sup> ; STEL (VLA-EC): 10 ppm; STEL (VLA-EC): 15 mg/m <sup>3</sup> ;
Switzerland	TWA-MAK: 2 ppm; TWA-MAK: 3 mg/m <sup>3</sup> ; STEL-KZGW: 4 ppm; STEL-KZGW: 6 mg/m <sup>3</sup> ;
U.S. - OSHA - Final PELs - Ceiling Limits	5 ppm 7 mg/m <sup>3</sup>
OSHA PEL	Ceiling: 5 ppm Ceiling: 7 mg/m <sup>3</sup> (vacated) Ceiling: 5 ppm (vacated) Ceiling: 7 mg/m <sup>3</sup>
United Kingdom	TWA: 1 ppm; gas and aerosol mist TWA: 2 mg/m <sup>3</sup> ; gas and aerosol mist STEL: 5 ppm; gas and aerosol mist STEL: 8 mg/m <sup>3</sup> ; gas and aerosol mist

## 8.2. Exposure controls

### Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

### Personal protective equipment

Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes. Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Tape gloves to coveralls or suit.

### Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

### Hand protection

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

### Skin and body protection

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

### Respiratory protection

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control

# SAFETY DATA SHEET

Product Name Aminocaproic Acid Injection (Hospira Inc.)  
Revision date 13-Jun-2025

Page 7 / 12  
Version 3

exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter).  
(Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).

**Thermal hazards** No information available.

**Environmental exposure controls** No information available.

## Section 9: PHYSICAL AND CHEMICAL PROPERTIES

### 9.1. Information on basic physical and chemical properties

<b>Physical state</b>	Liquid
<b>Color</b>	Colourless
<b>Odor</b>	No information available.
<b>Odor threshold</b>	No information available
<b>Property</b>	<b>Values</b>
<b>Melting point / freezing point</b>	No data available
<b>Boiling point or initial boiling point and boiling range</b>	No data available
<b>Flammability (solid, gas)</b>	No data available
<b>Lower and upper explosion limit/flammability limit</b>	
Lower explosion limit	No data available
Upper explosion limit	No data available
<b>Flash point</b>	No data available
<b>Autoignition temperature</b>	No data available
<b>Decomposition temperature</b>	
SADT (°C)	No data available
<b>pH</b>	6.8
pH (as aqueous solution)	No data available
<b>Kinematic viscosity</b>	No data available
Dynamic viscosity	No data available
<b>Solubility</b>	<b>Slightly Soluble:</b> methanol Soluble
<b>Vapor pressure</b>	No data available
<b>Density and/or relative density</b>	No data available
Bulk density	No data available
Liquid Density	No data available
<b>Vapor density</b>	No data available
<b>Particle characteristics</b>	
Particle Size	No information available
Particle Size Distribution	No information available

### 9.2. Other information

<b>Molecular formula</b>	Mixture
<b>Molecular weight</b>	Mixture

#### 9.2.1. Information with regard to physical hazard classes

No information available

#### 9.2.2. Other safety characteristics

No information available

## Section 10: STABILITY AND REACTIVITY

# SAFETY DATA SHEET

Product Name Aminocaproic Acid Injection (Hospira Inc.)  
Revision date 13-Jun-2025

Page 8 / 12  
Version 3

## 10.1. Reactivity

Reactivity No information available.

## 10.2. Chemical stability

Stability Stable under normal conditions.

## Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

## 10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

## 10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

## 10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

## 10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

## Section 11: TOXICOLOGICAL INFORMATION

### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

**General Information:** The information included in this section describes the potential hazards of the individual ingredients

**Short term** Not acutely toxic (based on animal data). Accidental ingestion may cause effects similar to those seen in clinical use.

**Known Clinical Effects:** Effects reported during clinical use include headache, dizziness, nausea, diarrhea, gastrointestinal disturbances, decrease in blood pressure (hypotension), ringing of the ears, nasal congestion, skin rash, changes in blood chemistry.

**Acute toxicity** Based on available data, the classification criteria are not met.

**Serious eye damage/eye irritation** Based on available data, the classification criteria are not met.

**Skin corrosion/irritation** Based on available data, the classification criteria are not met.

**Respiratory or skin sensitization** Based on available data, the classification criteria are not met.

**STOT - single exposure** Based on available data, the classification criteria are not met.

**STOT - repeated exposure** Based on available data, the classification criteria are not met.

**Reproductive toxicity** Based on available data, the classification criteria are not met.

**Germ cell mutagenicity** Based on available data, the classification criteria are not met.

**Carcinogenicity** Based on available data, the classification criteria are not met.

**Aspiration hazard** Based on available data, the classification criteria are not met.

### Acute Toxicity: (Species, Route, End Point, Dose)

#### Aminocaproic Acid

Rat Oral LD50 > 10,000 mg/kg

Mouse Oral LD50 12,000 mg/kg

Dog Oral LD50 > 7000 mg/kg

Rat Intravenous LD50 3200 mg/kg

Mouse Intravenous LD50 3000 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg ( Rat )	-	-
+ Hydrochloric Acid	238 - 277 mg/kg ( Rat )	> 5010 mg/kg ( Rabbit )	= 1.68 mg/L ( Rat ) 1 h

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not



# SAFETY DATA SHEET

Product Name Aminocaproic Acid Injection (Hospira Inc.)  
Revision date 13-Jun-2025

Page 9 / 12  
Version 3

achievable at the highest dose used in the test.

## **Irritation / Sensitization: (Study Type, Species, Severity)**

### **Aminocaproic Acid**

Eye Irritation Mild Moderate

### **+ Hydrochloric Acid**

Skin irritation Severe

Eye irritation Severe

## **Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

### **Aminocaproic Acid**

Reproductive & Fertility Rat Oral ~ 500 mg/kg/day LOAEL Fertility

## **Genetic Toxicity: (Study Type, Cell Type/Organism, Result)**

### **+ Hydrochloric Acid**

Bacterial Mutagenicity (Ames) *Salmonella* Negative

*In Vivo* Micronucleus Rat Negative

### **Carcinogenicity**

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

See below

### **+ Hydrochloric Acid**

IARC

Group 3

## **11.2. Information on other hazards**

### **11.2.1. Endocrine disrupting properties**

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

### **11.2.2. Other information**

**Other adverse effects**

No information available.

## **Section 12: ECOLOGICAL INFORMATION**

### **Environmental Overview:**

The environmental impact of this product has not been fully investigated.

### **12.1. Toxicity**

### **12.2. Persistence and degradability**

**Persistence and degradability**

No information available.

### **12.3. Bioaccumulative potential**

**Bioaccumulation**

No information available.

### **12.4. Mobility in soil**

**Mobility in soil**

No information available.

# SAFETY DATA SHEET

Product Name Aminocaproic Acid Injection (Hospira Inc.)  
Revision date 13-Jun-2025

Page 10 / 12  
Version 3

## 12.5. Results of PBT and vPvB assessment

**PBT and vPvB assessment** Based on available data, the classification criteria are not met.

Chemical name	PBT and vPvB assessment
Aminocaproic Acid	PBT assessment does not apply
+ Hydrochloric Acid	Not PBT/vPvB PBT assessment does not apply

## 12.6. Endocrine disrupting properties

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

## 12.7. Other adverse effects

**Other adverse effects** No information available.

**PMT or vPvM properties** Based on available data, the classification criteria are not met.

## Section 13: DISPOSAL CONSIDERATIONS

### 13.1. Waste treatment methods

#### Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

## Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

**Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.**

<b>UN number:</b>	Not applicable
<b>UN proper shipping name:</b>	Not applicable
<b>Transport hazard class(es):</b>	Not applicable
<b>Packing group:</b>	Not applicable
<b>Environmental Hazard(s):</b>	Not applicable

## Section 15: REGULATORY INFORMATION

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

CERCLA/SARA Section 313 de minimus %  
California Proposition 65  
TSCA

Not Listed  
Not Listed  
Present

# SAFETY DATA SHEET

Product Name Aminocaproic Acid Injection (Hospira Inc.)  
Revision date 13-Jun-2025

Page 11 / 12  
Version 3

<b>EINECS</b>	231-791-2
<b>AICS</b>	Present
Aminocaproic Acid	
<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	200-469-3
<b>AICS</b>	Present
+ Hydrochloric Acid	
<b>CERCLA/SARA Section 313 de minimus %</b>	1.0 %
<b>Hazardous Substances RQs</b>	5000 lb
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	231-595-7
<b>AICS</b>	Present
<b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b>	Schedule 5 Schedule 6

## National regulations

### Germany

#### **Chemical Prohibition Ordinance (ChemVerbotsV)**

Not applicable

### **TRGS 905**

Not applicable

### Switzerland

**Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018** Not applicable

**Storage of Hazardous Material** Not applicable

**WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20** Not applicable

**Major Accidents Ordinance SR 814.012** Not applicable

### **European Union**

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

#### **Authorizations and/or restrictions on use:**

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
Aminocaproic Acid 60-32-2	75	-
+ Hydrochloric Acid 7647-01-0	75	-

#### **Persistent Organic Pollutants**

Not applicable

Chemical name	Lower-tier requirements (tons)	Upper-tier requirements (tons)
+ Hydrochloric Acid 7647-01-0	25	250

#### **Ozone-depleting substances (ODS) Regulation (EU) 2024/590**

Not applicable.

# SAFETY DATA SHEET

Product Name Aminocaproic Acid Injection (Hospira Inc.)  
Revision date 13-Jun-2025

Page 12 / 12  
Version 3

Chemical name	Biocidal Products Regulation (EU) No 528/2012 (BPR)
+ Hydrochloric Acid 7647-01-0	Product-type 2: Disinfectants and algacides not intended for direct application to humans or animals

## Explosives Precursors Marketing and Use (2019/1148)

Not applicable

### Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory  
**DSL/NDSL** - Canadian Domestic Substances List/Non-Domestic Substances List  
**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances  
**ENCS** - Japan Existing and New Chemical Substances  
**IECSC** - China Inventory of Existing Chemical Substances  
**KECL** - Korean Existing Chemicals Inventory  
**PICCS** - Philippines Inventory of Chemicals and Chemical Substances  
**AICS** - Australian Inventory of Chemical Substances  
**NZIoC** - New Zealand Inventory of Chemicals  
**TCSI** - Taiwan Chemical Substance Inventory

## 15.2. Chemical safety assessment

**Chemical Safety Report** No information available

## Section 16: OTHER INFORMATION

### Key or legend to abbreviations and acronyms used in the safety data sheet

### Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H314 - Causes severe skin burns and eye damage H331 - Toxic if inhaled

**Data Sources:** Pfizer proprietary drug development information. Publicly available toxicity information.

**Reason for revision** Updated Section 3 - Composition / Information on Ingredients. Added Pfizer OEL (Section 8). Updated Section 12 - Ecological Information. Updated Section 11 - Toxicology Information.

**Revision date** 13-Jun-2025

**Prepared By** Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.